Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2010 2
2011 1
2012 1
2013 2
2014 2
2015 1
2016 3
2017 2
2020 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Drug Hepatotoxicity: Newer Agents.
Bunchorntavakul C, Reddy KR. Bunchorntavakul C, et al. Clin Liver Dis. 2017 Feb;21(1):115-134. doi: 10.1016/j.cld.2016.08.009. Epub 2016 Oct 14. Clin Liver Dis. 2017. PMID: 27842767 Review.
Idiosyncratic hepatotoxicity is one of the most common reasons for an approved drug being restricted. ...Nevertheless, cases of severe hepatotoxicity have been reported due to some of these newer agents, including, trastuzumab, ipilimumab, infliximab, imatinib, bosu …
Idiosyncratic hepatotoxicity is one of the most common reasons for an approved drug being restricted. ...Nevertheless, cases of sever …
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Zhang-Roper R, Wang R, Pineda JA, Heera J. Rockstroh JK, et al. Antivir Ther. 2017;22(3):263-269. doi: 10.3851/IMP3116. Epub 2016 Dec 7. Antivir Ther. 2017. PMID: 27924779 Free article. Clinical Trial.
BACKGROUND: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. ...CONCLUSIONS: Use of maraviroc did not in …
BACKGROUND: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc …
Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC, Rockstroh JK, Hardy WD. Wasmuth JC, et al. Expert Opin Drug Saf. 2012 Jan;11(1):161-74. doi: 10.1517/14740338.2012.640670. Epub 2011 Nov 26. Expert Opin Drug Saf. 2012. PMID: 22118500 Review.
This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. AREAS COVERED: The PubMed database was searched using the keywords 'maraviroc' and 'HIV'. ...All RCTs showed an excellent safety profile for maraviroc in the treatmen …
This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. AREAS COVERED: The PubMed database was s …
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
Rockstroh JK, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA. Rockstroh JK, et al. HIV Clin Trials. 2015 Mar-Apr;16(2):72-80. doi: 10.1179/1528433614Z.0000000011. HIV Clin Trials. 2015. PMID: 25923596 Free article. Clinical Trial.
Treatment-related hepatobiliary adverse events were reported in one and two subjects receiving maraviroc and placebo, respectively; discontinuations due to treatment-related AEs occurred in four and two subjects receiving maraviroc and placebo, respectively; two dea …
Treatment-related hepatobiliary adverse events were reported in one and two subjects receiving maraviroc and placebo, respectively; d …
Hepatic safety and tolerability in the maraviroc clinical development program.
Ayoub A, Alston S, Goodrich J, Heera J, Hoepelman AI, Lalezari J, Mchale M, Nelson M, van der Ryst E, Mayer H. Ayoub A, et al. AIDS. 2010 Nov 13;24(17):2743-50. doi: 10.1097/QAD.0b013e32833f9ce2. AIDS. 2010. PMID: 20935557
Many agents used to treat HIV disease are associated with the potential for hepatotoxicity. The hepatic effects of maraviroc were analyzed across all Pfizer-sponsored maraviroc clinical trials, in which 2350 volunteers received maraviroc. ...No patient …
Many agents used to treat HIV disease are associated with the potential for hepatotoxicity. The hepatic effects of maraviroc w …
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM, Rockstroh JK. Emmelkamp JM, et al. Eur J Med Res. 2007 Oct 15;12(9):409-17. Eur J Med Res. 2007. PMID: 17933722 Review.
The expanded access program for maraviroc was opened in June 2007 in several European countries. The FDA approved the use of maraviroc for antiretroviral therapy of HIV on the 7th of august, 2007. ...Concerns have risen about possible class-specific long-term advers …
The expanded access program for maraviroc was opened in June 2007 in several European countries. The FDA approved the use of marav …
Maraviroc first-line therapy for HIV infection. Too risky.
[No authors listed] [No authors listed] Prescrire Int. 2010 Nov;19(110):252-4. Prescrire Int. 2010. PMID: 21284357 Review.
This trial fails to answer important questions regarding the adverse effects of maraviroc, such as hepatotoxicity, infections, cancer, and cardiovascular disorders. ...In practice, first-line use of maraviroc is imprudent, as it depends on a test of uncertain …
This trial fails to answer important questions regarding the adverse effects of maraviroc, such as hepatotoxicity, infections, …
Hepatoxicity of new antiretrovirals: a systematic review.
Surgers L, Lacombe K. Surgers L, et al. Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):126-33. doi: 10.1016/j.clinre.2013.02.008. Epub 2013 Mar 21. Clin Res Hepatol Gastroenterol. 2013. PMID: 23522569 Review.
Within the past 5 years, new drugs from both previously established and novel therapeutic classes have been released that tend to be safer and more efficient than their former combinations. Although hepatotoxicity was one of the most common side effects from initial antire …
Within the past 5 years, new drugs from both previously established and novel therapeutic classes have been released that tend to be safer a …
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S. Ndegwa S. Issues Emerg Health Technol. 2007 Dec;(110):1-8. Issues Emerg Health Technol. 2007. PMID: 18080399
(1) Maraviroc belongs to a new class of antiretroviral drugs designed to block entry of HIV-1 into CD4+ T-cells via the CCR5 coreceptor. ...No significant increases in cardiovascular events, hepatotoxicity, infections or malignancies have been reported with short-te …
(1) Maraviroc belongs to a new class of antiretroviral drugs designed to block entry of HIV-1 into CD4+ T-cells via the CCR5 corecept …
Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?
Huntington S, Thorne C, Anderson J, Newell ML, Taylor G, Pillay D, Hill T, Tookey P, Sabin C. Huntington S, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19486. doi: 10.7448/IAS.17.4.19486. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25393995 Free PMC article.
INTRODUCTION: High rates of hepatotoxicity have been observed among HIV-positive pregnant women using antiretroviral therapy (ART). However, the extent to which pregnancy affects the risk of ART-induced hepatotoxicity is unclear since studies in this area have gener …
INTRODUCTION: High rates of hepatotoxicity have been observed among HIV-positive pregnant women using antiretroviral therapy (ART). H …
16 results